David Malcom Rodman, the Chief Medical Officer of $MLYS, sold 2,966 shares of the company on 04-14-2025 for an estimated $40,613. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.4% of their shares of this class of stock. Following this trade, they now own 120,086 shares of this class of $MLYS stock.
$MLYS Insider Trading Activity
$MLYS insiders have traded $MLYS stock on the open market 15 times in the past 6 months. Of those trades, 3 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $MLYS stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA purchased 1,296,296 shares for an estimated $17,499,996
- SRINIVAS AKKARAJU purchased 600,000 shares for an estimated $8,100,000
- BIOCAPITAL GP, LLC SAMSARA purchased 600,000 shares for an estimated $8,100,000
- DAVID MALCOM RODMAN (Chief Medical Officer) has made 0 purchases and 7 sales selling 97,645 shares for an estimated $1,502,657.
- JON CONGLETON (Chief Executive Officer) has made 0 purchases and 2 sales selling 33,652 shares for an estimated $352,885.
- ADAM SCOTT LEVY (CFO and Secretary) has made 0 purchases and 3 sales selling 21,514 shares for an estimated $227,548.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MLYS Hedge Fund Activity
We have seen 55 institutional investors add shares of $MLYS stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 1,002,941 shares (+1015.8%) to their portfolio in Q4 2024, for an estimated $12,346,203
- OCTAGON CAPITAL ADVISORS LP removed 600,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $7,386,000
- INTEGRAL HEALTH ASSET MANAGEMENT, LLC added 519,000 shares (+145.8%) to their portfolio in Q4 2024, for an estimated $6,388,890
- JPMORGAN CHASE & CO added 482,174 shares (+2251.5%) to their portfolio in Q4 2024, for an estimated $5,935,561
- ADAMS STREET PARTNERS LLC removed 402,847 shares (-26.3%) from their portfolio in Q4 2024, for an estimated $4,959,046
- STEMPOINT CAPITAL LP added 400,101 shares (+inf%) to their portfolio in Q4 2024, for an estimated $4,925,243
- ORBIMED ADVISORS LLC removed 391,302 shares (-19.5%) from their portfolio in Q4 2024, for an estimated $4,816,927
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MLYS Analyst Ratings
Wall Street analysts have issued reports on $MLYS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 04/02/2025
To track analyst ratings and price targets for $MLYS, check out Quiver Quantitative's $MLYS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
